{
    "id": "351f5ae8-19c0-c78c-e063-6294a90a731d",
    "indications": "celecoxib capsules indicated",
    "contraindications": "• lowest effective shortest duration consistent individual patient treatment goals ( 2.1 ) • oa : 200 mg daily 100 mg twice daily ( 2.2 , 14.1 ) • rheumatoid arthritis : 100 mg 200 mg twice daily ( 2.3 , 14.2 ) • jra : 50 mg twice daily patients 10 kg 25 kg . 100 mg twice daily patients 25 kg ( 2.4 , 14.3 ) • : 200 mg daily single dose 100 mg twice daily . effect observed 6 weeks , trial 400 mg ( single divided doses ) may benefit ( 2.5 , 14.4 ) • ap pd : 400 mg initially , followed 200 mg dose needed first day . subsequent days , 200 mg twice daily needed ( 2.6 , 14.5 ) hepatic impairment : reduce daily dose 50 % patients moderate hepatic impairment ( child-pugh class b ) . ( 2.7 , 8.6 , 12.3 ) poor metabolizers cyp2c9 substrates : consider dose reduction 50 % ( alternative management jra ) patients known suspected cyp2c9 poor metabolizers , ( 2.7 , 8.8 , 12.3 ) .",
    "warningsAndPrecautions": "celecoxib capsules 200 mg size ' 2 ' , white opaque cap , white opaque body 'c6 ' imprinted yellow band cap '200mg ' imprinted yellow band body available follows : bottles 100 capsules ndc 72162-2489-01 bottles 500 capsules ndc 72162-2489-05 storage store 20° 25°c ( 68° 77°f ) ; excursions permitted 15° 30°c ( 59° 86°f ) [ usp controlled room temperature ] . repackaged/relabeled : bryant ranch prepack , inc. burbank , ca 91504",
    "adverseReactions": "• celecoxib capsules contraindicated following patients : known hypersensitivity ( e.g . , anaphylactic serious skin ) celecoxib , components product [ ( 5.7 , 5.9 ) ] . • history asthma , urticaria , allergic-type taking aspirin nsaids . severe , sometimes fatal , anaphylactic nsaids , reported patients [ ( 5.7 , 5.8 ) ] . • setting cabg surgery [ ( 5.1 ) ] . • patients demonstrated allergic-type sulfonamides [ ( 5.7 ) ] .",
    "ingredients": [
        {
            "name": "GELATIN",
            "code": "2G86QN327L"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "POVIDONE",
            "code": "FZ989GH94E"
        },
        {
            "name": "SODIUM LAURYL SULFATE",
            "code": "368GB5141J"
        },
        {
            "name": "HYDROXYPROPYL CELLULOSE",
            "code": "RFW2ET671P"
        },
        {
            "name": "CROSPOVIDONE",
            "code": "68401960MK"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "SHELLAC",
            "code": "MB5IUD6JUA"
        },
        {
            "name": "PROPYLENE GLYCOL",
            "code": "6DC9Q167V3"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT"
        },
        {
            "name": "SODIUM HYDROXIDE",
            "code": "55X04QC32I"
        },
        {
            "name": "CELECOXIB",
            "code": "JCX84Q7J1L"
        }
    ],
    "organization": "Bryant Ranch Prepack",
    "name": "celecoxib",
    "effectiveTime": "20250514",
    "indications_original": "Celecoxib capsules are indicated",
    "contraindications_original": "• Use the lowest effective dosage for shortest duration consistent with individual patient treatment goals ( 2.1 ) • OA: 200 mg once daily or 100 mg twice daily ( 2.2 , 14.1 ) • RA: 100 mg to 200 mg twice daily ( 2.3 , 14.2 ) • JRA: 50 mg twice daily in patients 10 kg to 25 kg. 100 mg twice daily in patients more than 25 kg ( 2.4 , 14.3 ) • AS: 200 mg once daily single dose or 100 mg twice daily. If no effect is observed after 6 weeks, a trial of 400 mg (single or divided doses) may be of benefit ( 2.5 , 14.4 ) • AP and PD: 400 mg initially, followed by 200 mg dose if needed on first day. On subsequent days, 200 mg twice daily as needed ( 2.6 , 14.5 ) Hepatic Impairment: Reduce daily dose by 50% in patients with moderate hepatic impairment (Child-Pugh Class B). ( 2.7 , 8.6 , 12.3 ) Poor Metabolizers of CYP2C9 Substrates: Consider a dose reduction by 50% (or alternative management for JRA) in patients who are known or suspected to be CYP2C9 poor metabolizers, ( 2.7, 8.8 , 12.3 ).",
    "warningsAndPrecautions_original": "Celecoxib Capsules 200 mg\n                  Size '2', White opaque cap, white opaque body with 'C6' imprinted on the yellow band on the cap and '200mg' imprinted on the yellow band on the body and are available as follows:\n                  \n                  Bottles of 100 Capsules NDC 72162-2489-01\n  \nBottles of 500 Capsules NDC 72162-2489-05\n \n                  \n                  \n                     \n                        Storage \n                     \n                     \nStore at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) [See USP Controlled Room Temperature].\n \n                  \n                  Repackaged/Relabeled by:\n  \nBryant Ranch Prepack, Inc.\n  \nBurbank, CA 91504",
    "adverseReactions_original": "• Celecoxib capsules are contraindicated in the following patients: Known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to celecoxib, any components of the drug product [\n \n  see Warnings and Precautions (\n  \n   5.7,\n  \n   5.9)\n \n  ]. \n    • History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs. Severe, sometimes fatal, anaphylactic reactions to NSAIDs, have been reported in such patients [\n \n  see Warnings and Precautions (\n  \n   5.7,\n  \n   5.8)\n \n  ]. \n    • In the setting of CABG surgery [\n \n  see Warnings and Precautions (\n  \n   5.1)\n \n  ]. \n    • In patients who have demonstrated allergic-type reactions to sulfonamides [\n \n  see Warnings and Precautions (\n  \n   5.7)\n \n  ]."
}